Gavi Backs Merck & Co's Ebola Vaccine Candidate
This article was originally published in Scrip
Gavi, the global vaccine alliance, has promised Merck & Co. Inc. that it has a customer for its Ebola vaccine candidate rVSV?G-ZEBOV-GP, the only vaccine with Phase III data for the deadly viral infection, through the signing of an 'advance purchase commitment'.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.